Kymera Therapeutics (KYMR) pipeline and stated timing

Name in SEC filings: Kymera Therapeutics, Inc.

Pipeline at a glance

Program	Event	Stage	Stated timing	Filing
KT-579	/data readout	Phase 1	fourth quarter of 2026	EX-99.1 · Aug 5, 2026
KT-621	Topline/data readout	Stage not stated	year-end 2026	EX-99.1 · Aug 5, 2026

Source: ORION, orionbiotechai.com/company/KYMR, data as of Oct 13, 2026
https://www.orionbiotechai.com/company/KYMR

Nearest upcoming stated timing: KT-579 · Topline/data readout · fourth quarter of 2026

SEC sources last checked Oct 13, 2026.

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

KT-579

Matched

Topline/data readoutfourth quarter of 2026

Stage: Phase 1SEC filing · “Phase 1”

Public float: $2,294,800,000 · as of Jun 30, 2025 · SEC filing

Phase 1 clinical trial in healthy volunteers , with data expected in the fourth quarter of 2026

EX-99.1 · Filed Aug 5, 2026 · Last checked Oct 13, 2026

Source details

Accession 0001193125-26-333834

Alert me · Calendar: same stage and window-end month (2026-12)

KT-621

Matched

Topline/data readoutyear-end 2026

Stage: Not stated

Public float: $2,294,800,000 · as of Jun 30, 2025 · SEC filing

its expected topline data readout by six months to year-end 2026

EX-99.1 · Filed Aug 5, 2026 · Last checked Oct 13, 2026

Source details

Accession 0001193125-26-333834

Alert me · Calendar: same stage and window-end month (2026-12)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of Oct 19, 2026.

Program / event	Stated period and SEC wording	Disclosure in stated period
KT-579Clinical results	fourth quarter of 2026 “Phase 1 clinical trial in healthy volunteers , with data expected in the fourth quarter of 2026” Filed Aug 5, 2026 · EX-99.1	Still within period As of Oct 19, 2026
KT-621Clinical results	year-end 2026 “its expected topline data readout by six months to year-end 2026” Filed Aug 5, 2026 · EX-99.1	Still within period As of Oct 19, 2026
KT-579Clinical results	second half of 2026 “data expected to be reported in the second half of 2026” Filed Jan 13, 2026 · EX-99.1	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
KT-621Clinical results	mid-2027 “BROADEN2 Phase 2b AD trial in 2026, with data expected to be reported by mid-2027” Filed Jan 13, 2026 · EX-99.1	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
KT-621Clinical results	mid-2027 “BROADEN2 Phase 2b trial in AD has been initiated with topline data expected by mid-2027” Filed Nov 4, 2025 · EX-99.1	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Retained company announcements

Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.

Historical catalog checked Sep 26, 2026.

No historical announcement trail is retained for this company in this catalog.

Selected registry record

KT-621 · NCT07823205

Condition in the selected registry record: Healthy Participants
Phase in the selected registry record: Phase 1
Identity checked: Sep 26, 2026

Original ClinicalTrials.gov record · Open the selected study

Retained company–study identity sources

Scope of retained company and registry evidence

These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.

Coverage and identity checks

Watch KYMR

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for KYMR. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window: The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date: The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q: First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original: The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status: One of seven labels set by founder review of the original filings. Definitions: Methodology.

See KYMR in the calendar · Review labels and methodology